(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.18%.
Celcuity's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast CELC's revenue for 2026 to be $2,185,977,790, with the lowest CELC revenue forecast at $824,236,982, and the highest CELC revenue forecast at $3,552,745,613. On average, 11 Wall Street analysts forecast CELC's revenue for 2027 to be $18,377,603,835, with the lowest CELC revenue forecast at $7,579,190,640, and the highest CELC revenue forecast at $32,329,985,074.
In 2028, CELC is forecast to generate $36,449,719,884 in revenue, with the lowest revenue forecast at $18,237,427,478 and the highest revenue forecast at $56,602,246,425.